

DAFTAR PUSTAKA

- Abbasi, M., Moghtadaie, A. and Miratashi Yazdi, S. A. (2021) 'Factors Affecting Vagus Nerve Stimulation Outcomes in Epilepsy', *Neurology Research International*. Edited by J. Bronstein, 2021, pp. 1–12. doi: 10.1155/2021/9927311.
- American Academy of Pediatrics (2021) *Principles of Child Health, American Academy of Pediatrics*. Available at: <https://www.aap.org> (Accessed: 24 September 2024).
- Aronica, E. *et al.* (2023) 'Epilepsy and Brain Tumors: Two Sides of the Same Coin', *Journal of the Neurological Sciences*, 446, p. 120584. doi: 10.1016/j.jns.2023.120584.
- Beghi, E. *et al.* (2019) 'Global, Regional, and National Burden of Epilepsy, 1990–2016: a Systematic Analysis for the Global Burden of Disease Study 2016', *The Lancet Neurology*, 18(4), pp. 357–375. doi: 10.1016/S1474-4422(18)30454-X.
- Beghi, E. (2020) 'The Epidemiology of Epilepsy', *Neuroepidemiology*, 54(2), pp. 185–191. doi: 10.1159/000503831.
- Bhosale, U. A. *et al.* (2014) 'Study of Effects of Antiepileptic Therapy on Various Biochemical and Hematological Parameters Patients Suffering of Epilepsy', *International Journal of Basic & Clinical Pharmacology*, 3(1), pp. 79–85. doi: 10.5455/2319-2003.ijbcp20140207.
- Chamberlain, J. M. *et al.* (2020) 'Efficacy of Levetiracetam, Fosphenytoin, and Valproate for Established Status Epilepticus by Age Group (ESETT): a Double-Blind, Responsive-Adaptive, Randomised Controlled Trial', *The Lancet*, 395(10231), pp. 1217–1224. doi: 10.1016/S0140-6736(20)30611-5.
- Curry, B., Mican, L. and Smith, T. L. (2018) 'Phenytoin-Induced Chronic Liver Enzyme Elevation and Hepatic Fibrosis: A Case Report', *Mental Health Clinician*, 8(4), pp. 184–187. doi: 10.9740/mhc.2018.07.184.
- Czuczwar, S. J. (2022) *Epilepsy*. Edited by S. J. Czuczwar. Brisbane: Exon Publications. doi: 10.36255/exon-publications-epilepsy.
- Dean, L. and Kane, M. (2021) 'Phenytoin Therapy and HLA-B*15:02 and CYP2C9 Genotype', *Medical Genetics Summaries*, pp. 1–16.
- Donnellan, E. P. *et al.* (2024) 'The 2017 and 2022 ILAE Epilepsy Classification Systems Identify Needs and Opportunities in Care: a Pediatric Hospital-Based Study', *Epilepsy and Behavior*, 157(March), p. 109804. doi: 10.1016/j.yebeh.2024.109804.
- El-Shafie, A. M. *et al.* (2023) 'Impact of Two Ketogenic Diet Types in Refractory Childhood Epilepsy', *Pediatric Research*, 94(6), pp. 1978–1989. doi: 10.1038/s41390-023-02554-w.
- Fan, J. *et al.* (2019) 'Research Progress of Vagus Nerve Stimulation in the Treatment of Epilepsy', *CNS Neuroscience & Therapeutics*, 25(11), pp. 1222–1228. doi: 10.1111/cns.13209.
- Fisher, R. S. *et al.* (2014) 'ILAE Official Report: a Practical Clinical Definition of Epilepsy', *Epilepsia*, 55(4), pp. 475–482. doi: 10.1111/epi.12550.
- Fisher, R. S., Cross, J. H., D'Souza, C., *et al.* (2017) 'Instruction Manual for the ILAE 2017 Operational Classification of Seizure Types', *Epilepsia*, 58(4), pp. 531–542.

- doi: 10.1111/epi.13671.
- Fisher, R. S., Cross, J. H., French, J. A., *et al.* (2017) 'Operational Classification of Seizure Types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology', *Epilepsia*, 58(4), pp. 522–530. doi: 10.1111/epi.13670.
- Fisher, R. S. (2017) 'The New Classification of Seizures by the International League Against Epilepsy 2017', *Current Neurology and Neuroscience Reports*, 17(6), pp. 1–6. doi: 10.1007/s11910-017-0758-6.
- Gupta, M. and Tripp, J. (2024) *Phenytoin*. Treasure Island (FL): StatPearls Publishing.
- Hardin, A. P. and Hackell, J. M. (2017) 'Age Limit of Pediatrics', *Pediatrics*, 140(3), p. e20172151.
- Hermans, M. *et al.* (2022) 'Evaluation of the Effect of Phenobarbital Administration on the Biochemistry Profile, with a Focus on Serum Liver Values, in Epileptic Cats', *Journal of Feline Medicine and Surgery*, 24(6), pp. 530–538. doi: 10.1177/1098612X211037431.
- Huff, J. S. and Murr, N. I. (2023) *Seizure*, StatPearls Publishing. Treasure Island (FL). Available at: <https://www.ncbi.nlm.nih.gov/books/NBK430765/>.
- Hussein, R. R. S. *et al.* (2013) 'Effect of Antiepileptic Drugs on Liver Enzymes', *Beni-Suef University Journal of Basic and Applied Sciences*, 2(1), pp. 14–19. doi: 10.1016/j.bjbas.2013.09.002.
- ILAE (2017) *Epilepsy 2017 - From Bench to Bedside*. 16th edn, International League Against Epilepsy. 16th edn. Edited by F. J. Rugg-Gunn and H. B. Stapley. London. Available at: <http://ilaebritish.org.uk/content/uploads/2017/10/Epilepsy-Notes-PDF-Book-2017-Proof-5.compressed.pdf>.
- Iorga, A. and Horowitz, B. Z. (2023) *Phenytoin Toxicity*. Treasure Island (FL): StatPearls Publishing.
- Kalas, M. A. *et al.* (2021) 'Abnormal Liver Enzymes: A Review for Clinicians', *World Journal of Hepatology*, 13(11), pp. 1688–1698. doi: 10.4254/wjh.v13.i11.1688.
- Kemendikbud (2016) *Epilepsi, Kamus Besar Bahasa Indonesia (KBBI)*. Available at: <https://kbbi.kemdikbud.go.id/entri/epilepsi> (Accessed: 20 September 2024).
- Kementerian Kesehatan Republik Indonesia (2017) 'KEPUTUSAN MENTERI KESEHATAN REPUBLIK INDONESIA NOMOR HK.01.07/MENKES/367/2017 TENTANG PEDOMAN NASIONAL PELAYANAN KEDOKTERAN TATA LAKSANA EPILEPSI PADA ANAK'. Indonesia.
- Keret, A. *et al.* (2017) 'Posttraumatic Epilepsy: Long-Term Follow-Up of Children with Mild Traumatic Brain Injury.', *Journal of neurosurgery. Pediatrics*, 20(1), pp. 64–70. doi: 10.3171/2017.2.PEDS16585.
- Kliegman, R. M. and St. Geme III, J. W. (2024) *Nelson Textbook of Pediatrics*. 22nd edn. Philadelphia: Elsevier.
- Kline, M. W. *et al.* (2018) *Rudolph's Pediatrics*. 23rd edn. Houston: McGraw-Hill Education.
- Koepp, M. J. *et al.* (2023) 'Antiepileptogenesis After Stroke—Trials and Tribulations: Methodological Challenges and Recruitment Results of a Phase II Study with Eslicarbazepine Acetate', *Epilepsia Open*, 8(3), pp. 1190–1201. doi: 10.1002/epi4.12735.

- Lala, V., Zubair, M. and Minter, D. A. (2024) *Liver Function Tests*, StatPearls Publishing. Treasure Island (FL). Available at: <http://www.ncbi.nlm.nih.gov/pubmed/31628070>.
- Leavy, A. and Mateos, E. M. J. (2020) 'Perinatal Brain Injury', *Cells*, 9, p. 2640. doi: 10.32388/3V0CIP.
- Lewis, C. B., Patel, P. and Adams, N. (2024) *Phenobarbital*, StatPearls Publishing. Treasure Island (FL).
- Liu, G. *et al.* (2023) 'Long-Term Follow-Up of Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus in Adults: a Randomized Clinical Trial', *Epilepsy Research*, 195, p. 107187. doi: 10.1016/j.epilepsyres.2023.107187.
- Liu, W., Li, H. and Lin, S. (2024) 'Research Hotspots and Frontiers of Alcohol and Epilepsy: A Bibliometric Analysis', *Neuropsychopharmacology Reports*, 44(2), pp. 342–355. doi: 10.1002/npr2.12421.
- Marcdante, K. J., Kliegman, R. M. and Schuh, A. M. (2022) *Nelson Essentials of Pediatrics*. 9th edn. Milwaukee: Elsevier.
- Mcwilliam, M., Asuncion, R. M. D. and Khalili, Y. Al (2024) *Idiopathic (Genetic) Generalized Epilepsy*. Treasure Island (FL): StatPearls Publishing.
- Meseguer, E. S. *et al.* (2021) 'Valproic Acid-Induced Liver Injury: A Case-Control Study from a Prospective Pharmacovigilance Program in a Tertiary Hospital', *Journal of Clinical Medicine*, 10(6), p. 1153. doi: 10.3390/jcm10061153.
- Muthaffar, O. Y. *et al.* (2021) 'Valproic Acid for Children below 2 Years of Age with Epilepsy', *Neurosciences*, 26(4), pp. 357–365. doi: 10.17712/nsj.2021.4.20210075.
- National Institute of Neurological and Stroke (2024) *Epilepsy and Seizures*, National Institute of Health. Available at: <https://www.ninds.nih.gov/health-information/disorders/epilepsy-and-seizures>.
- Neligan, A. *et al.* (2023) 'Prognosis of Adults and Children Following a First Unprovoked Seizure', *Cochrane Database of Systematic Reviews*, 2023(1). doi: 10.1002/14651858.CD013847.pub2.
- P, P. *et al.* (2023) 'Study on the Hepatoprotective Activity of Embelia Ribes on D-Galactosamine Induced Hepatotoxic Rats', *Journal of Pharmacology & Clinical Research*, 9(3). doi: 10.19080/JPCR.2023.09.555765.
- Perhimpunan Dokter Spesialis Saraf Indonesia (2019) *Pedoman Tata Laksana Epilepsi*. 6th edn, Airlangga University Press. 6th edn. Edited by K. Kusumastuti, S. Gunadharma, and E. Kustiowati. Surabaya.
- Presiden Republik Indonesia (2014) 'UNDANG-UNDANG REPUBLIK INDONESIA NOMOR 35 TAHUN 2014 TENTANG PERUBAHAN ATAS UNDANG-UNDANG NOMOR 23 TAHUN 2002 TENTANG PERLINDUNGAN ANAK'.
- Putri, R. H. and Putranti, A. H. (2021) 'Efek Samping Polifarmasi Asam Valproat dan Topiramate Dibandingkan Monofarmasi Asam Valproat pada Pasien Epilepsi', *Sari Pediatri*, 23(4), p. 247. doi: 10.14238/sp23.4.2021.247-54.
- Rabiei, D. L. *et al.* (2022) 'The Effects of Self-Management Education and Support on Self-Efficacy, Self-Esteem, and Quality of Life Among Patients with Epilepsy', *Seizure: European Journal of Epilepsy*, 102, pp. 96–104. doi:

- 10.1016/j.seizure.2022.09.023.
- Rahman, M., Awosika, A. O. and Nguyen, H. (2024) *Valproic Acid*, StatPearls Publishing. Treasure Island (FL). Available at: <http://epilepsyontario.org/about-epilepsy/treatments/medications/valproic-acid/>.
- Rastin, C., Schenkel, L. C. and Sadikovic, B. (2023) 'Complexity in Genetic Epilepsies: a Comprehensive Review', *International Journal of Molecular Sciences*, 24(19), p. 14606. doi: 10.3390/ijms241914606.
- Riney, K. *et al.* (2022) 'International League Against Epilepsy Classification and Definition of Epilepsy Syndromes with Onset at a Variable Age: Position Statement by the ILAE Task Force on Nosology and Definitions', *Epilepsia*, 63(6), pp. 1443–1474. doi: 10.1111/epi.17240.
- Sastroasmoro, S. and Ismael, S. (2011) *Dasar-dasar Metodologi Penelitian Klinis Edisi Ke-4*. Jakarta: CV. Sagung Seto.
- Scheffer, I. E. *et al.* (2017) 'Commission for Classification and Terminology', *Epilepsia*, 58(4), pp. 512–521. doi: 10.1111/epi.13709.ILAE.
- Semple, B. D., Dill, L. K. and O'Brien, T. J. (2020) 'Immune Challenges and Seizures: How Do Early Life Insults Influence Epileptogenesis?', *Frontiers in Pharmacology*, 11, pp. 1–14. doi: 10.3389/fphar.2020.00002.
- Sharma, R., Kumar, R. and Sharma, P. (2016) 'Study of Clinical Profile and Biochemical Parameters in Children on Antiepileptic Drugs: a Brain-Liver-Kidney Tri-Axis in Epilepsy', *Open Journal of Medicine & Healthcare (OJMH)*, 1(3), pp. 11–22. Available at: https://www.researchgate.net/publication/318876609_STUDY_OF_CLINICAL_PROFILE_AND_BIOCHEMICAL_PARAMETERS_IN_CHILDREN_ON_ANTI_EPILEPTIC_DRUGS_A_BRAIN-LIVER-KIDNEY_TRI-AXIS_IN_EPILEPSY.
- Sharpe, C. *et al.* (2020) 'Levetiracetam Versus Phenobarbital for Neonatal Seizures: a Randomized Controlled Trial', *Pediatrics*, 145(6), p. e20193182. doi: 10.1542/peds.2019-3182.
- Sheng, J. *et al.* (2017) 'Drug-Resistant Epilepsy and Surgery', *Current Neuropharmacology*, 16(1), pp. 17–28. doi: 10.2174/1570159X15666170504123316.
- Skibiski, J., Patel, P. and Abdijadid, S. (2024) *Barbiturates*, StatPearls Publishing. Treasure Island (FL).
- Specchio, N. *et al.* (2022) 'International League Against Epilepsy Classification and Definition of Epilepsy Syndromes with Onset in Childhood: Position Paper by the ILAE Task Force on Nosology and Definitions', *Epilepsia*, 63(6), pp. 1398–1442. doi: 10.1111/epi.17241.
- Tanaka, T. *et al.* (2024) 'Pathophysiology, Diagnosis, Prognosis, and Prevention of Poststroke Epilepsy', *Neurology*, 102(11), p. e209450. doi: 10.1212/WNL.0000000000209450.
- Tien, Y.-C. *et al.* (2015) 'Dose of Phenobarbital and Age of Treatment at Early Life are Two Key Factors for the Persistent Induction of Cytochrome P450 Enzymes in Adult Mouse Liver', *Drug Metabolism and Disposition*, 43(12), pp. 1938–1945. doi: 10.1124/dmd.115.066316.
- Vezzani, A. *et al.* (2016) 'Infections, Inflammation and Epilepsy', *Acta Neuropathologica*, 131(2), pp. 211–234. doi: 10.1007/s00401-015-1481-5.

- Vidaurre, J., Gedela, S. and Yarosz, S. (2017) 'Antiepileptic Drugs and Liver Disease', *Pediatric Neurology*, 77, pp. 23–36. doi: 10.1016/j.pediatrneurol.2017.09.013.
- WHO (2024a) *Children*, World Health Organization. Available at: <https://www.who.int/> (Accessed: 23 September 2024).
- WHO (2024b) *Epilepsy*, World Health Organization. Available at: <https://www.who.int/news-room/fact-sheets/detail/epilepsy> (Accessed: 20 September 2023).
- Zhu, M.-M. *et al.* (2017) 'The Pharmacogenomics of Valproic Acid', *Journal of Human Genetics*, 62(12), pp. 1009–1014. doi: 10.1038/jhg.2017.91.

LAMPIRAN

Lampiran 1 Surat Permohonan Izin Penelitian



KEMENTERIAN PENDIDIKAN KEBUDAYAAN,
RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN
FAKULTAS KEDOKTERAN
JL. PERINTIS KEMERDEKAAN KM. 10, MAKASSAR 90245
TELEPON (0411) 586200, (6 SALURAN), 584200, FAX (0411) 585188
Laman: www.unhas.ac.id

Nomor : 24272/UN4.6.8/PT.01.04/2024

18 Desember 2024

Hal : Permohonan Izin Penelitian An. Vivi Tantriawan

Yth. Direktur RSUP Dr. Wahidin Sudirohusodo

Dengan hormat, disampaikan bahwa mahasiswa Program Studi Pendidikan Dokter Fakultas Kedokteran Universitas Hasanuddin di bawah ini :

N a m a : Vivi Tantriawan

N i m : C011211098

bermaksud melakukan penelitian di RSUP Dr. Wahidin Sudirohusodo dengan judul penelitian "Evaluasi Pengaruh Obat Antiepilepsi Terhadap Enzim Fungsi Hati pada Pasien Anak Penderita Epilepsi di RSUP Dr. Wahidin Sudirohusodo Makassar Tahun 2024"

Sehubungan hal tersebut kiranya yang bersangkutan dapat diberi izin untuk melakukan Penelitian dalam rangka penyelesaian studinya.

Demikian permohonan kami, atas bantuan dan kerjasamanya disampaikan terima kasih.

Ketua Program Studi S1
Pendidikan Dokter
Fakultas Kedokteran



dr. Ririn Nislawati, M.Kes.,Sp.M
NIP 198101182009122003

Lampiran 2 Surat Rekomendasi Persetujuan Etik



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
 KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
 RSPTN UNIVERSITAS HASANUDDIN
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
 Contact Person: dr. Agussalim Bukhari.,MMed.PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

**REKOMENDASI PERSETUJUAN ETIK**

Nomor : 964/UN4.6.4.5.31/ PP36/ 2024

Tanggal: 6 Nopember 2024

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH24110912		No Sponsor	
Peneliti Utama	Vivi Tantriawan		Sponsor	
Judul Peneliti	EVALUASI PENGARUH OBAT ANTIEPILEPSI TERHADAP ENZIM FUNGSI HATI PADA PASIEN ANAK PENDERITA EPILEPSI DI RSUP DR. WAHIDIN SUDIROHUSODO MAKASSAR TAHUN 2024			
No Versi Protokol	1	Tanggal Versi	4 Nopember 2024	
No Versi PSP		Tanggal Versi		
Tempat Penelitian	RSUP Dr.Wahidin Sudirohusodo Makassar			
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku	Frekuensi review lanjutan	
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)		6 Nopember 2024 sampai 6 Nopember 2025	
Sekretaris KEP Universitas Hasanuddin	dr. Firdaus Hamid, PhD, SpMK(K)			

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laport SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 3 Data Sampel Penelitian

No.	Jenis Kelamin	Usia	Epilepsi	Jenis OAE	Lama Konsumsi SGOT (Sebelum)	SGPT (Sebelum)	SGOT (Sesudah)	SGPT (Sesudah)	
1	L	7 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	12 bulan	22	19	15	9
2	P	1 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	12 bulan	32	11	49	12
3	P	5 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	7 bulan	94	24	33	31
4	P	15 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	3 bulan	19	13	49	115
5	P	1 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	22 bulan	38	21	40	34
6	P	1 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	12 bulan	49	13	77	105
7	P	1 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	14 bulan	27	16	33	20
8	P	13 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	8 bulan	18	11	12	13
9	P	14 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	18 bulan	40	41	20	11
10	P	3 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	7 bulan	278	251	25	16
11	L	1 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	6 bulan	119	197	35	42
12	P	0 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	3 bulan	21	41	34	37
13	P	3 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	13 bulan	29	23	32	18
14	L	7 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	4 bulan	30	30	20	16
15	P	0 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	3 bulan	58	82	35	53
16	P	5 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	8 bulan	94	24	33	31
17	P	0 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	7 bulan	99	29	55	12
18	L	3 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	16 bulan	46	26	43	25
19	P	4 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	5 bulan	163	72	85	28
20	L	1 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	3 bulan	43	17	35	36
21	L	17 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	4 bulan	21	51	113	76
22	P	15 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	5 bulan	16	12	32	30
23	P	4 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	4 bulan	48	49	44	36
24	P	2 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	3 bulan	163	12	26	14
25	L	0 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	5 bulan	39	54	30	37
26	P	2 tahun	G40.9[Epilepsy, unspecified]	Fenitoin	3 bulan	35	43	58	69
27	P	1 tahun	G40.9[Epilepsy, unspecified]	Fenobarbital	3 bulan	33	21	104	65
28	P	1 tahun	G40.9[Epilepsy, unspecified]	Fenobarbital	10 bulan	23	10	32	13
29	L	0 tahun	G40.9[Epilepsy, unspecified]	Fenobarbital	7 bulan	120	112	30	37
30	P	1 tahun	G40.9[Epilepsy, unspecified]	Fenobarbital	11 bulan	17	6	16	8
31	P	3 tahun	G40.9[Epilepsy, unspecified]	Fenobarbital	5 bulan	202	15	40	17
32	L	11 tahun	G40.9[Epilepsy, unspecified]	Fenobarbital	6 bulan	31	12	26	25
33	P	2 tahun	G40.9[Epilepsy, unspecified]	Fenobarbital	9 bulan	30	19	28	16
34	L	0 tahun	G40.9[Epilepsy, unspecified]	Fenobarbital	3 bulan	19	13	30	37
35	L	1 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	6 bulan	29	16	36	22
36	L	7 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	6 bulan	22	12	32	13
37	L	10 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	20 bulan	26	10	17	5
38	L	8 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	18 bulan	31	11	26	11
39	L	2 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	4 bulan	58	21	45	13
40	L	3 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	10 bulan	30	16	22	15
41	L	1 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	20 bulan	31	8	33	9
42	P	15 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	9 bulan	25	19	21	12
43	L	1 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	18 bulan	29	16	36	22
44	L	3 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	21 bulan	42	18	36	13
45	L	1 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	17 bulan	26	22	41	15
46	P	3 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	21 bulan	23	9	22	8
47	L	1 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	4 bulan	29	21	44	32
48	L	2 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	13 bulan	33	13	28	9
49	P	1 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	15 bulan	46	14	38	16
50	L	1 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	8 bulan	46	28	39	12
51	P	17 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	7 bulan	34	13	17	5
52	P	4 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	5 bulan	22	11	19	14
53	L	14 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	6 bulan	28	18	42	31
54	P	2 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	4 bulan	23	9	33	29
55	L	13 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	22 bulan	22	13	20	15
56	L	3 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	13 bulan	52	17	44	15
57	L	3 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	9 bulan	49	27	40	22
58	P	2 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	9 bulan	31	12	28	12
59	P	6 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	12 bulan	61	13	48	7
60	P	6 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	5 bulan	85	23	57	8
61	L	1 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	3 bulan	164	78	44	29
62	L	2 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	22 bulan	27	14	28	15
63	L	3 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	16 bulan	46	23	33	22
64	P	14 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	17 bulan	24	13	43	19
65	L	3 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	13 bulan	55	32	24	9
66	P	4 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	4 bulan	23	14	21	8
67	P	9 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	15 bulan	30	7	23	10
68	L	12 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	5 bulan	32	25	36	23
69	L	10 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	17 bulan	22	13	32	40
70	P	15 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	3 bulan	21	13	53	52
71	L	5 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	5 bulan	43	22	29	10
72	L	8 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	15 bulan	34	18	26	11
73	L	2 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	3 bulan	86	43	68	44
74	L	9 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	3 bulan	24	9	18	9
75	L	8 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	3 bulan	32	11	24	10
76	P	3 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	22 bulan	27	10	22	8
77	L	6 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	9 bulan	56	11	46	19
78	P	8 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	6 bulan	77	20	24	32
79	L	3 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	16 bulan	30	16	22	15
80	P	8 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	19 bulan	23	13	26	12
81	P	1 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	8 bulan	59	55	64	46
82	L	4 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	5 bulan	36	37	46	22
83	L	4 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	7 bulan	30	21	25	24
84	P	17 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	9 bulan	34	13	17	5
85	L	2 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	4 bulan	58	21	45	13
86	L	14 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	5 bulan	14	11	42	31
87	P	12 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	6 bulan	20	17	19	10
88	L	3 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	15 bulan	49	27	40	22
89	P	14 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	5 bulan	24	13	43	19
90	L	3 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	13 bulan	37	15	24	9
91	P	3 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	17 bulan	55	30	37	14
92	L	7 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	12 bulan	34	32	33	18
93	P	4 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	13 bulan	58	26	28	14
94	P	10 tahun	G40.9[Epilepsy, unspecified]	Asam valproat	14 bulan	35	27	23	10

Lampiran 4 Biodata Penulis



Nama Lengkap : Vivi Tantriawan
 NIM : C011211098
 Tempat, Tanggal Lahir : Makassar, 13 April 2003
 Jenis Kelamin : Perempuan
 Agama : Kristen Protestan
 Alamat : Jl. Alimalaka lorong 288A nomor 1 B
 No. Telepon : 082188435660
 Program Studi : Pendidikan Dokter Umum
 Fakultas : Kedokteran
 Email : vivitantriawan@gmail.com
 Riwayat Pendidikan :

No.	Jenjang Pendidikan	Nama Institusi	Jurusan	Tahun Masuk
1.	SD	SD Kristen Gamaliel Makassar	-	2009
2.	SMP	SMP Kristen Gamaliel Makassar	-	2015
3.	SMA	SMA Kristen Gamaliel Makassar	Matematika dan Ilmu Pengetahuan Alam (MIPA)	2018
4.	Perguruan Tinggi	Universitas Hasanuddin	Pendidikan Dokter Umum	2021